Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort
Frederik Vandenberghe, Monia Guidi, Eva Choong, Armin von Gunten, Philippe Conus, Chantal Csajka, Chin B Eap
CLINICAL PHARMACOKINETICS | ADIS INT LTD | Published : 2015
BACKGROUND: High interindividual variability in plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, may lead to suboptimal drug concentration. OBJECTIVE: Using a population pharmacokinetic approach, we aimed to characterize the genetic and non-genetic sources of variability affecting risperidone and 9-hydroxyrisperidone pharmacokinetics, and relate them to common side effects. METHODS: Overall, 150 psychiatric patients (178 observations) treated with risperidone were genotyped for common polymorphisms in NR1/2, POR, PPARα, ABCB1, CYP2D6 and CYP3A genes. Plasma risperidone and 9-hydroxyrisperidone were measured, and clinical data and common clinical chemistry..View full abstract
Awarded by Swiss National Research Foundation
This work has been funded in part by the Swiss National Research Foundation (CBE and PC: 320030-120686 and 324730-144064).